## **Chapter 6. Signal Transduction** (signaling)

Recommended Article: 【Biology】 [Biology Table of Contents](https://jb243.github.io/pages/1457)

---

**1.** [Overview](#1-overview)

**2.** [Transduction](#2-transduction)

**3.** [**Receptor 1.** G Protein-Coupled Receptors](#3-g-protein-coupled-receptors-gpcr)
 
**4.** [**Receptor 2.** Tyrosine Kinase Receptors](#4-tyrosine-kinase-receptors-receptor-tyrisine-kinase-rtk)
 
**5\.** [**Receptor 3.** Serine/Threonine Kinase Receptors](#5-serine-threonine-kinase-receptors)

**6.** [**Receptor 4.** Intracellular Receptors](#6-intracellular-receptors)
 
**7.** [**Receptor 5.** Ion Channel Receptors](#7-ion-channels)

**8.** [**Receptor 6.** Adhesion Receptors](#8-adhesion-receptors)
 
**9.** [**Receptor 7.** Other Receptors](#9-other-receptors)

**10.** [Signal Transduction Enhancers](#10-signal-transduction-enhancers)

**11.** [Signal Transduction Inhibitors](#11-signal-transduction-inhibitors)

---

**a.** [Apoptosis](https://jb243.github.io/pages/1426)

---

<br>

## **1\. Overview**

⑴ Life activities are composed of around [200-300](https://www.cheme.cornell.edu/faculty-directory/matthew-delisa#:~:text=life%20depends%20on%20200-300%20core%20biological%20processes) core biological pathways.

⑵ Process

> ① **Step 1.** Reception

> ② **Step 2.** Transduction: Signal amplification through phosphorylation cascade is a representative process.

> ③ **Step 3.** Response: Reactions in the nucleus are related to genes, while reactions in the cytoplasm are related to proteins.

⑶ Characteristics

> ① Specificity: Ligand specificity

> ② Integration

> ③ Amplification: Reaction amplification

> ④ Sensitivity attenuation and adaptation

> ⑤ Communication

⑷ Epistasis

> ① Epistasis in signal transduction: The signal that acts last is considered to have higher epistasis.

> ② [Epistasis in genetics](https://jb243.github.io/pages/72#4-non-memdel-genetics): The gene that acts first is considered to have higher epistasis.

<br>

<br>

## **2\. Transduction**

⑴ Overview

> ① **Case 1.** When the signal attaches to Ser or Thr of a signaling protein: Possible due to the presence of -OH group.

>> ○ Src

>> ○ FAK

>> ○ JAK

>> ○ PTP

>> ○ STP

> ② **Case 2.** When the signal attaches to Tyr of a signaling protein: Possible due to the presence of -OH group.

>> ○ **Case 1** and **Case 2** do not occur simultaneously.

> ③ **Case 3.** CheA

>> ○ Histidine kinase

>> ○ Not involved in serine/threonine pathways.

⑵ **Type 1.** MAPK (Mitogen-Activated Protein Kinases)

> ① Overview

>> ○ Common principle: MAPKKK → MAPKK → MAPK

>> ○ Located near the nucleus.

> ② **1-1.** ERK1/2 (Extracellular Signal-Regulated Kinase) Module: Mammalian MAPK cascade

>> ○ 1<sup>st</sup>. Growth factors, mitogens

>> ○ 2<sup>nd</sup>. MAPKKK stage: A-Raf, B-Raf, C-Raf

>> ○ 3<sup>rd</sup>. MAPKK stage: MKK1/2

>> ○ 4<sup>th</sup>. MAPK stage: ERK1 (MAPK3), ERK2 (MAPK1)

>> ○ 5<sup>th</sup>. Proliferation, differentiation, division

> ③ **1-2.** JNK (c-Jun N-terminal kinase) / p38 Module: Mammalian MAPK cascade

>> ○ 1<sup>st</sup>. Stress stimuli

>> ○ 2<sup>nd</sup>. MAPKKK stage: MEKK1/4, ASK1/2, MLK1/2/3

>> ○ 3<sup>rd</sup>. MAPKK stage: MKK3/6, MKK4, MKK7

>> ○ 4<sup>th</sup>. MAPK stage: p38α/β/γ/δ, JNK1/2/3

>> ○ 5<sup>th</sup>. Cellular apoptosis, inflammatory response, cell differentiation, cell cycle arrest

> ④ **1-3.** ERK5 Module: Mammalian MAPK cascade

>> ○ 1<sup>st</sup>. Morphological stimuli

>> ○ 2<sup>nd</sup>. MAPKKK stage: MEKK2/3

>> ○ 3<sup>rd</sup>. MAPKK stage: MKK5

>> ○ 4<sup>th</sup>. MAPK stage: ERK5

>> ○ 5<sup>th</sup>. Formation of endothelial cell lumen

> ⑤ **1-4.** Yeast MAPK cascade

>> ○ α-factor pheromone → Ste11 → Ste7 → Fus3 → Cell cycle arrest, mating

>> ○ Starvation → Ste11 → Ste7 → Kss1 → Filament elongation

>> ○ Hyperosmotic stress → Ssk2/22 → Pbs2 → Hog1 → Glycerol synthesis

>> ○ Hypoosmotic stress → Bck1 → MKK1/2 → Mpk1 → Cell wall remodeling

>> ○ Nutrient deprivation → Cak1 → Smk1 → Meiosis, Spore formation

 ⑶ **Type 2.** CDK (Cyclin-Dependent Kinase)

> ① Function: [Regulation of cell cycle](https://jb243.github.io/pages/71#2-vertical-transfer-of-genes-cell-division)

> ② Types and related regulators

>> ○ Cyclin A, B, D, E

>> ○ CDK 1, 2, 4, 6

>> ○ MPF, CDC, CDI, APC

>> ○ Myc

>> ○ p53, p21, mdm

>> ○ Bax, cytochrome C, Caspase

>> ○ Rb, E2F

>> ○ WEE1, CDC25

⑷ **Type 3.** NF-κB pathway

> ① 1<sup>st</sup>. NF-κB forms a complex with Iκ-B protein in the cytoplasm under normal conditions.

>> ○ Iκ-B inhibits the movement of NF-κB to the nucleus.

> ② 2<sup>nd</sup>. Signal molecules like TNF-α trimer bind to receptors.

> ③ 3<sup>rd</sup>. IKK (inhibitor kappa kinase) is activated.

> ④ 4<sup>th</sup>. Serine-threonine kinase RIP is activated.

> ⑤ 5<sup>th</sup>. Iκ-B is activated and degraded in the cytoplasm.

> ⑥ 6<sup>th</sup>. NF-κB is dissociated from Iκ-B and moves to the nucleus.

> ⑦ 7<sup>th</sup>. NF-κB produces proteins related to macrophage inflammation.

>> ○ Macrophages have pro-inflammatory M1 and anti-inflammatory M2 types.

>> ○ NF-κB helps macrophages transition to the M1 type.

 ⑸ **Type 4.** mTOR (Mammalian Target of Rapamycin)

> ① Serine/threonine kinases evolutionarily conserved from yeast.

> ② Inhibited by rapamycin.

> ③ PI3K → Akt → mTOR → Cell division, cell proliferation, cell survival, angiogenesis, nutrient uptake, energy production

 ⑹ **Type 5.** GSK3

 ⑺ **Type 6.** CLK

<br>

<br>

## **3\. G Protein-Coupled Receptors (GPCR)**

 ⑴ Overall Structure

<br>

![image](https://github.com/user-attachments/assets/7ec023e0-423e-4f0e-a902-650b0f0fe7f0)

**Figure 1.** Structure of G Protein-Coupled Receptors 

<br>

 ⑵ **Component 1.** Membrane Receptors (GPCR)

> ① **Diversity of Cell Membrane Receptors**

> ② **Structure:** Penetrates the cell membrane 7 times (7TM, 7 trans-membrane). In other words, there are 7 α-helices.

> ③ **Attachment of G Proteins:** G proteins are attached to the 5th and 6th transmembrane regions.

> ⑶ **Composition 2.** G Protein

> ① **Location:** Exposed to the cytoplasm, attached to the 5th and 6th transmembrane regions of GPCRs.

> ② **Function:** Converts GTP to GDP.

>> ○ Activates enzymes that generate 2nd messengers after being activated by GPCRs, contributing to signal transduction.

>> ○ Binds with GTP for activation, and with GDP for inactivation.

>> ○ Activates 2nd messengers like PKA, PKC, PKG, opens or closes ion channels (olfaction).

>> ○ There's a connection between directly opening ion channels and sensitivity to olfaction.

> ③ **Structure:** Composed of three subunits: Gα, Gβ, Gγ.

>> ○ Gβ and Gγ subunits are always together.

>> ○ Upon GPCR activation, GDP bound to the αβγ complex is released, causing α and βγ subunits to dissociate, activating the G protein.

>> ○ βγ subunit activates adenylate cyclase (AC) and phospholipase C (PLC).

> ④ Various types of α subunits exist.

> ⑤ **Type 1.** Gαs (stimulatory): Activates adenylate cyclase (AC).

>> ○ 1<sup>st</sup>. G protein moves to GPCR and gets activated.

>> ○ 2<sup>nd</sup>. αs subunit of G protein activates adenylate cyclase (AC).

>> ○ 3<sup>rd</sup>. AC converts ATP to cAMP.

>> ○ 4<sup>th</sup>. cAMP activates PKA, initiating phosphorylation cascade.

> ⑥ **Type 2.** Gαi (inhibitory): Inhibits adenylate cyclase (AC).

>> ○ 1<sup>st</sup>. βγ complex dissociates from α subunit due to GPCR.

>> ○ 2<sup>nd</sup>. αi subunit inhibits adenylate cyclase (AC).

>> ○ 3<sup>rd</sup>. Down-signaling occurs.

>> ○ Forms muscarinic receptors.

> ⑦ **Type 3.** Gq: Activates phospholipase C (PLC).

>> ○ 1<sup>st</sup>. Signal molecule binding to G protein-coupled receptor activates phospholipase C (PLC).

>> ○ 2<sup>nd</sup>. PLC breaks down PIP2 into DAG and IP3.

>> ○ 3<sup>rd</sup>. Both DAG and IP3 act as secondary messengers, activating different pathways.

>> ○ 4<sup>th</sup>. IP3 acts as ligand for IP3-gated channels on ER, releasing Ca2+ into the cytoplasm.

>> ○ 5<sup>th</sup>. Released Ca2+ binds to calmodulin or acts as a secondary messenger to activate PKC and other proteins. DAG also influences protein phosphorylation.

>> ○ 6<sup>th</sup>. G protein's α subunit can hydrolyze GTP, stopping signal transmission.

> ⑧ **Type 4.** Gαt

> ⑨ **Type 5.** GαO: Inhibits adenylate cyclase (AC).

> ⑩ **Type 6.** Gαolf: Activates adenylate cyclase (AC).

> ⑪ **Type 7.** Gg

> ⑫ **Type 8.** G11: Activates phospholipase C (PLC).

> ⑬ **Type 9.** G12,13

> ⑷ **Composition 3.** Small GTPase

> ① Similar function as G proteins but smaller in size: About 1/10 the size of G proteins.

> ① **Example 1.** Rho: Attaches cell membrane receptors to the cytoskeleton, regulating cell shape and movement.

> ② **Example 2.** Ras

>> ○ Activated by tyrosine kinases, involved in signal transduction pathways.

>> ○ Important in activating MAPK.

>> ○ Normal function: Cell proliferation, differentiation, survival.

>> ○ Subtypes: H-Ras, K-Ras, N-Ras.

>> ○ Ras genes are oncogenes.

> ③ **Example 3.** ARF1, ARF6: Involved in autophagosome formation.

> ⑸ **Composition 4.** Regulators

> ① PKA (Protein Kinase A)

>> ○ Serine/threonine kinase activated by cAMP.

>> ○ Increases fatty acid oxidation by acting on ligase.

> ② PKC (Protein Kinase C)

>> ○ Kinase activated by DAG.

>> ○ Phosphorylates glycogen synthase, among others.

> ③ PKG (Protein Kinase G)

>> ○ Opens K+ channels and closes Ca2+ channels via PKG.

> ④ cAMP: A secondary messenger

>> ○ There are also G proteins that regulate cAMP.

>> ○ Serotonin can increase cAMP by more than 100 times.

>> ○ Adenyl cyclase: Converts ATP to cAMP.

>> ○ PDE (phosphodiesterase): Breaks down cAMP.

> ⑤ Adenylyl Cyclase (AC)

>> ○ AC converts ATP to cAMP.

>> ○ cAMP directly activates PKA, a type of Ser/Thr kinase: Mainly in skeletal muscles.

>> ○ When the signal from AC disappears, cAMP is converted to AMP by a phosphodiesterase.

>> ○ Gαs: Activates adenyl cyclase.

>> ○ Gαi: Inhibits adenyl cyclase.

> ⑥ Phospholipase C (PLC)

> ⑦ Calmodulin (CaM)

>> ○ Extracellular Ca2+ / Intracellular Ca2+ = 10,000.

>> ○ Found in the cytoplasm of all eukaryotic cells, from plants and fungi to protists.

>> ○ Binding with Ca2+ changes its structure, enabling interaction with various intracellular proteins.

>> ○ Particularly, Ca2+/calmodulin-dependent kinases (CaM-kinase) activated by calmodulin phosphorylate specific proteins, influencing various cellular responses.

>> ○ Example: NO.

> ⑧ PIP2: Phosphatidyl inositol 4,5-bisphosphate.

> ⑨ DAG: Diacylglycerol.

> ⑩ IP3: Inositol triphosphate.

> ⑪ **GAP** (GTPase accelerating protein)

>> ○ Assists Gα in GTPase function by Ras.

>> ○ Inactivates G proteins.

> ⑫ **GEF** (Guanine-nucleotide exchange factor)

>> ○ Catalyzes the binding of Ras and GTP.

>> ○ Assists in the reactivation of G proteins.

>> ○ GDP → GTP (i.e., brings in new GTP).

 ⑹ **Example 1.** Glycogen breakdown regulation: cAMP.

<br>

![image](https://github.com/user-attachments/assets/21a83f3c-7606-48ff-a4ea-a49846305ee9)

**Figure 2.** Schematic of the adrenaline signaling pathway [Footnote:2].

<br>

> ① 1<sup>st</sup>. Epinephrine (adrenaline) binds to a type of GPCR called epinephrine receptor.

> ② 2<sup>nd</sup>. G protein moves to the GPCR and gets activated.

> ③ 3<sup>rd</sup>. Gαs subunit of the G protein activates adenylyl cyclase (AC).

> ④ 4<sup>th</sup>. AC converts ATP to cAMP.

> ⑤ 5<sup>th</sup>. cAMP activates PKA, initiating a phosphorylation cascade.

> ⑥ 6<sup>th</sup>. Phosphorylation cascade eventually activates glycogen phosphorylase, leading to glycogen breakdown.

> ⑦ 7<sup>th</sup>. Glucose production.

 ⑺ **Example 2.** Metabotropic acetylcholine receptor (muscarinic receptor).

> ① Overview

>> ○ Found at the terminal synapses of all parasympathetic postganglionic fibers.

>> ○ Also found in the brain, heart, and smooth muscles.

>> ○ Distributes throughout the autonomic ganglia except in cardiac muscle fibers.

>> ○ Responds to muscarine.

>> ○ **Type 1:** M1, M2, M5: Excitatory receptors.

>> ○ **Type 2:** M3, M4: Inhibitory receptors.

> ② Mechanism

>> ○ 1<sup>st</sup>. Gαi is activated.

>> ○ 2<sup>nd</sup>. Acetylcholine (Ach) binding to the muscarinic receptor causes separation of the βγ subunits from the α subunit.

>> ○ 3<sup>rd</sup>. αi subunit inactivates adenylyl cyclase: Interaction with Gαs protein.

>> ○ 4<sup>th</sup>. β-γ complex of the G protein binds to K+ ion channels, leading to K+ efflux: Slows heart rate.

> ③ Examples

>> ○ **Example 1:** Acetylcholine receptors found in the parasympathetic nervous system.

>> ○ **Example 2:** Found in cardiac cells and postganglionic parasympathetic neurons.

>> ○ **Example 3:** Nitric oxide (NO) and [vascular relaxation](https://jb243.github.io/pages/88).

> ④ Inhibitors

>> ○ Atropine: Muscarinic antagonist, sympathetic nerve stimulation.

>> ○ Sarin, DIFP, Tabun: Covalent inhibitors of acetylcholine esterase.

 ⑻ **Example 3.** Adrenergic receptor (adrenoceptor).

> ① Binds catecholamine hormones such as norepinephrine, epinephrine, beta-blockers, beta-agonists, alpha-agonists.

> ② Adrenergic receptors mainly located in arterioles, with different functions and types based on location.

>> ○ Liver cells: Epinephrine beta receptors → Increase blood glucose.

>> ○ Skeletal muscle blood vessels: Epinephrine beta receptors → Vasodilation.

>> ○ Intestinal blood vessels: Epinephrine alpha receptors → Vasoconstriction.

>> ○ Cardiac muscles and other smooth muscle arterioles: Epinephrine beta receptors → Arteriolar dilation → Increased blood flow → Contraction of cardiac muscles and smooth muscles.

>> ○ Visceral organ arterioles: Epinephrine alpha receptors → Arteriolar constriction → Decreased blood flow to visceral organs → Visceral relaxation.

> ③ Total of 9 subtypes: α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, β3.

>> ○ α1 couples with Gαq protein. Found in arterioles supplying visceral organs.

>> ○ α2 couples with Gαi protein.

>> ○ All β receptors couple with Gαs protein.

>> ○ β1: Found only in the heart. Located in sinoatrial node and ventricles.

>> ○ β2: Supplies skeletal muscles and located in blood vessels.

>> ○ Both β2 and β3 also couple with Gαi protein.

 ⑼ **Example 4.** Inhibition of G protein function.

> ① Cholera toxin: AB toxin

>> ○ 1<sup>st</sup>. B subunit of AB toxin reacts with GPCR, A enters the cell.

>> ○ 2<sup>nd</sup>. GPCR activates Gαs.

>> ○ 3<sup>rd</sup>. Gαs reacts with ADP-ribose, reducing GTPase activity.

>> ○ 4<sup>th</sup>. Reduced GTPase activity increases adenylyl cyclase activity.

>> ○ 5<sup>th</sup>. Adenylyl cyclase generates cAMP from ATP.

>> ○ 6<sup>th</sup>. Increased cAMP activates PKA.

>> ○ 7<sup>th</sup>. ATP binds to the R domain of CFTR channel via PKA, opening the channel.

>> ○ 8<sup>th</sup>. Increased Cl- secretion and water efflux cause diarrhea and dehydration.

> ② Pertussis toxin

>> ○ 1<sup>st</sup>. ADP-ribose reacts with Gi, decreasing Gi activity.

>> ○ 2<sup>nd</sup>. Adenylyl cyclase activity increases.

>> ○ 3<sup>rd</sup>. Increased cAMP decreases secretion of chemical messengers in infected cells.

>> ○ 4<sup>th</sup>. Diminished immune cell recruitment increases infection and triggers respiratory issues.

 ⑽ **Example 5.** Other examples of GPCRs.

> ① [Brown adipose tissue norepinephrine receptor](https://jb243.github.io/pages/81#:~:text=%E2%97%8B%20%EC%A2%85%EB%A5%98%202.-,%EA%B0%88%EC%83%89%EC%A7%80%EB%B0%A9,-%3A%20%ED%98%88%EB%A5%98%EB%A1%9C%20%EC%9D%B8%ED%95%B4)

> ② [Transduction in liver cells](https://jb243.github.io/pages/1289#:~:text=3<sup>rd</sup>.-,%ED%8A%B8%EB%9E%9C%EC%8A%A4%EB%93%80%EC%8B%A0,-\(G%20%EB%8B%A8%EB%B0%B1%EC%A7%88\)%20%ED%99%9C%EC%84%B1%ED%99%94)

> ③ [Olfactory nerve cells](https://jb243.github.io/pages/1292#:~:text=2<sup>nd</sup>.-,GPCR,-%EC%9D%80%20%EB%82%AE%EC%9D%80%20%EB%86%8D%EB%8F%84%EC%9D%98)

> ④ [Somatostatin receptor](https://jb243.github.io/pages/89#:~:text=%E2%91%A2%20%EC%A2%85%EB%A5%98%203.-,%EC%86%8C%EB%A7%88%ED%86%A0%EC%8A%A4%ED%83%80%ED%8B%B4,-\(somatostatin%3B%20STT\)): SSTR1 ~ SSTR5

> ⑤ [FSH Receptor](https://jb243.github.io/pages/553#:~:text=%E2%91%B6%20%EC%97%AC%ED%8F%AC%EC%9E%90%EA%B7%B9%ED%98%B8%EB%A5%B4%EB%AA%AC\(-,FSH,-%2C%20follicle%20stimulating)

> ⑥ [Mechanisms Preventing Multiple Crystallization During Sea Urchin Development](https://jb243.github.io/pages/1448#:~:text=%EB%8B%A4%EC%88%98%EC%A0%95%20%EC%99%84%EB%A7%8C%20%EB%B0%A9%EC%A7%80%20\(-,%ED%94%BC%EC%B8%B5%EB%B0%98%EC%9D%91,-\)%C2%A0%3A)

<br>

<br>

## **4\. Tyrosine Kinase Receptors** (receptor tyrosine kinase, RTK)

 ⑴ **Component 1.** RTK

> ① TKD: tyrosine kinase domain

 ⑵ **Component 2.** Regulators

> ① rho: Attaches cell membrane receptors to the cytoskeleton to regulate cell shape and movement

> ② _Ras_ ( _rat sarcoma_ )

>> ○ Activated by tyrosine kinase to participate in signal transduction pathways

>> ○ Plays an important role in activating MAPK

>> ○ Normal functions: Cell proliferation, cell differentiation, cell survival

>> ○ Ras is divided into H-Ras, K-Ras, N-Ras, etc.

>> ○ One of the [oncogenes](https://jb243.github.io/pages/71#:~:text=%E2%97%8B%C2%A0%EC%98%88%203.-,Ras%C2%A0,-\(rat%20sarcoma\))

> ③ PI3K(PI3-kinase): Converts PI(4,5)-P2 to PI(3, 4, 5)P3, allowing PDK1 and Akt to bind

> ④ JAK-STAT: Involves STAT1,2, SH2

> ⑤ MAPK

> ⑥ Src family

> ⑦ FAK

> ⑧ myc

 ⑶ Mechanism

> ① 1<sup>st</sup>. Ligand binding: Growth factors bind to receptors

> ② 2<sup>nd</sup>. Autophosphorylation: Each receptor can phosphorylate itself while transferring phosphate to the opposite tyrosine

>> ○ Has an ATP binding site, so phosphorylation uses ATP

> ③ 3<sup>rd</sup>. Proteins like GRB2 bind and locate Sos factor

>> ○ Sos factor: Acts as a GEF, separating GDP from Ras and binding GTP to activate it

>> ○ GEF (guanine-nucleotide exchange factor): Aids in G-protein reactivation. GDP → GTP (i.e., brings in new GTP)

> ④ 4<sup>th</sup>. Sos factor activates Ras, and activated Ras activates Raf

>> ○ Nearly all receptor tyrosine kinases that bind growth factors activate Ras protein

> ⑤ 5<sup>th</sup>. Raf catalyzes MEK phosphorylation

>> ○ Raf is a serine/threonine kinase

> ⑥ 6<sup>th</sup>. MAPK is activated during MEK phosphorylation and then moves into the nucleus

>> ○ MAPK: Also known as ERK, responds sequentially

>> ○ ERK1/2: Inhibits feedback from GRB2 / SOS

> ⑦ 7<sup>th</sup>. Inactive transcription factor myc becomes activated, and cyclin D is generated

> ⑧ 8<sup>th</sup>. Such signaling is halted by removing phosphate from phosphorylated sites through tyrosine dephosphorylase

 ⑶ Tyrosine Kinase Inhibitors

> ① imatinib (Glivec)

> ② dasatinib (Sprycel)

> ③ sunitinib (Sutent)

> ④ nilotinib (Tasigna)

> ⑤ sorafenib (Nexavar)

> ⑥ temsirolimus (Torisel)

> ⑦ nintedanib: Treatment for idiopathic pulmonary fibrosis

> ⑧ pirfenidone: Treatment for idiopathic pulmonary fibrosis

 ⑷ **Example 1.** EGFR (epidermal growth factor receptor)

> ① **Component 1.** EGFR

>> ○ Also known as ErbB1 or HER-1

>> ○ Structure: 170 kDa glycoprotein

>>> ○ This protein is composed of 1186 amino acids, forming 1 polypeptide chain

>>> ○ Initial precursor consists of 1210 amino acids, forming 1 polypeptide chain

>> ○ 60-80% of colorectal cancers overexpress EGFR

> ② **Component 2.** EGF

>> ○ Structure: 6 kDa. Human EGF consists of 53 amino acids

> ③ EGFR Signaling Pathway

>> ○ 1<sup>st</sup>. When EGF and EGFR bind, it causes a change in structure, activating TKD.

>> ○ 2<sup>nd</sup>. Various types of signaling proteins bind to phosphorylated EGFR

>>> ○ **Type 1:** SH2 (src homology-2): The N-terminus of SH2 recognizes the sequence of tyrosine.

>>> ○ **Type 2:** Shc's PTB (phosphotyrosine binding) domain: The C-terminus of the PTB domain binds.

>> ○ 3<sup>rd</sup>. Major downstream signaling

>>> ○ Ras → Raf → ERK

>>> ○ PI3K → Akt → mTOR

<br>

![image](https://github.com/user-attachments/assets/2547584f-84bc-4319-8b74-2eeaeb00daed)

**Figure 3.** EGFR signaling pathway

<br>

> ④ Positive feedback regulators

>> ○ ERBB ligands: TGFα, HB-EGF, etc., increase expression after the signaling pathway

> ⑤ Negative feedback regulators

>> ○ DEP (density-enhanced phosphatase-1)

>> ○ SOCS5 (cytokine signaling-5)

> ⑥ Inhibitors

>> ○ Gefitinib (Iressa): An anticancer drug that inhibits EGFR-TKI (EGFR-tyrosine kinase inhibitor). FDA-approved

>> ○ Erlotinib (Tarceva)

>> ○ Cetuximab (Erbitux): FDA-approved

>>> ○ IgG1 isotype

>>> ○ Binding site: Q384, Q408, H409, K443, K465, I467, S468, F352, D355, P387

>>> ○ Has immunogenic activity

>> ○ Panitumumab (Vectibix): FDA-approved

>>> ○ IgG2 isotype

>>> ○ Binding site: P349, P362, D355, F412, I438

>>> ○ No immunogenic activity

>> ○ Lapatinib (Tyverb): Directly inhibits downstream signaling by inhibiting TKD. FDA-approved

>> ○ Afatinib: Directly inhibits downstream signaling by inhibiting the tyrosine-kinase domain. FDA-approved

>> ○ Sapitinib

 ⑸ **Example 2.** HER2 (erbB-2): Also known as CD340, Neu, Erbb2 (rodent), ERBB2 (human)

> ① Structure: (Extracellular) I - II - III - IV - Transmembrane domain - TKD (Intracellular)

>> ○ II: Dimerization domain

> ② Function

>> ○ Overexpression of HER2 leads to excessive cell proliferation through autophosphorylation: Associated with poor prognosis, tumor formation, etc.

>> ○ Overexpressed in 15-40% of ovarian cancer cases

> ③ Mechanism: Utilizes PI3-kinase signaling

> ④ Positive feedback regulators

>> ○ ERBB2: Once activated, subsequent activation is facilitated

>> ○ Heterodimer containing ERBB2

>> ○ ERBB ligands: TGFα, HB-EGF, etc., increase expression after the signaling pathway

> ⑤ Inhibitors

>> ○ Pertuzumab: Inhibits II, inhibiting receptor dimerization. FDA-approved

>> ○ Trastuzumab, margetuximab: Inhibits IV. Associated with ADCC. FDA-approved

>> ○ Trastuzumab emtansine (T-DM1): Conjugates anticancer drug with trastuzumab. FDA-approved

>> ○ Trastuzumab deruxtecan: Conjugates anticancer drug with trastuzumab. FDA-approved

>> ○ Lapatinib: Directly inhibits downstream signaling by inhibiting TKD. FDA-approved

>> ○ Afatinib: Directly inhibits downstream signaling by inhibiting TKD. FDA-approved

>> ○ Neratinib: Directly inhibits downstream signaling by inhibiting TKD. FDA-approved

>> ○ Sapitinib

>> ○ CI-1033

 ⑹ **Example 3.** HER3 (erbB-3)

> ① Inhibitors: Sapitinib

 ⑺ **Example 4.** IGF-1R (insulin-like growth factor receptor)

> ① Structure

>> ○ Extracellular ligand-binding domain: Contains two α subunits

>> ○ Transmembrane domain

>> ○ Cytoplasmic domain: Contains two β subunits

>> ○ Total of 3 disulfide bonds: α-α, α-β, α-β

>> ○ β subunits function as tyrosine kinases

> ② IGF-1R can bind to ligands IGF-1 and IGF-2

> ③ When IGF-1R is activated, the following three signaling pathways are activated

>> ○ STAT3

>> ○ PI3K → AKT (inhibited by PTE) → mTOR → S6K

>> ○ GRB2 → Ras / Raf → MEK → MAPK

> ④ IGF-1R promotes malignant tumors

> ⑤ Inhibitors: AXL1717, linsitinib (currently in phase 3 trials)

 ⑻ **Example 5.** IR (insulin receptor)

> ① Structure

>> ○ Extracellular ligand-binding domain: Contains two α subunits

>> ○ Transmembrane domain

>> ○ Cytoplasmic domain: Contains two β subunits

>> ○ Total of 3 disulfide bonds: α-α, α-β, α-β

>> ○ β subunits function as tyrosine kinases

> ② Experiment: In cancer cells like HepG2, both IGF-1R and IR are overexpressed, forming IGF-1R/IR heterodimers

>> ○ IGF-1R homodimer: Can bind to ligands IGF-1 and IGF-2

>> ○ IR homodimer: Can bind to ligands IGF-2 and insulin

>> ○ IGF-1R/IR heterodimer: Can bind to ligands IGF-1, IGF-2, and insulin

>> ○ IGF-1R/IR heterodimer has a broad ligand-binding site, making it sensitive to anticancer agents

>> ○ Anti-IGF1R antibody can inhibit the proliferation of cancer cells dependent on IGF-1R/IR heterodimers

 ⑼ **Example 6.** Bruton's tyrosine kinase: The drug ibrutinib targets this.

<br>

<br>

## **5. Serine/Threonine Kinase Receptors**

 ⑴ **Type 1.** TGF-β Receptors

> ① 1<sup>st</sup>. Formation of TGF-βRⅠ by binding TGF-β1 ligand and TGF-βRⅡ receptor

> ② 2<sup>nd</sup>. Activation of Smad2, Smad3 by TGF-βRⅠ: Inhibited by Smad7

> ③ 3<sup>rd</sup>. Activated Smad2, Smad3 act as transcription factors by binding Smad4

> ④ Function: Involved in wound healing, angiogenesis, immune regulation, cancer development

<br>

<br>

## **6. Intracellular Receptors**

 ⑴ Overview

> ① Binding: Lipophilic ligands (e.g., steroid hormones)

> ② Location: Inside the cytoplasm

> ③ Mechanism: Direct entry into the nucleus → Transcription factors

 ⑵ **Example 1.** PPAR (Peroxisome Proliferator-Activated Receptor)

> ① Structure: A/B domain (N-terminus) + C domain (conserved DNA-binding domain) + E domain (ligand-binding C-terminus)

> ② **Type 1.** PPARα: Abundant in liver, skeletal muscle, kidney, heart, and blood vessels; low in fat and cartilage

> ③ **Type 2.** PPARβ/δ: Expressed throughout the body, relatively high expression in brain, liver, and intestines

> ④ **Type 3.** PPARγ: Expressed in mammalian adipose tissue, vascular smooth muscle, heart muscle; important transcription factor regulating cell division

 ⑶ **Example 2.** [Prostaglandin Receptor (PtgR)](https://jb243.github.io/pages/86#:~:text=%E2%97%8B%204<sup>th</sup>.-,%ED%94%84%EB%A1%9C%EC%8A%A4%ED%83%80%EA%B8%80%EB%9E%80%EB%94%98,-%3A%20%EC%97%BC%EC%A6%9D%EB%B0%98%EC%9D%91\(%EC%97%B4%20%EB%B0%9C%EC%83%9D)

> ① Prostaglandin: Causes inflammation (fever), mucous secretion, headaches, blood clotting, smooth muscle contraction (uterine contraction in females)

> ② Prostaglandin is produced in almost all cells and acts as a local regulator due to its unstable molecular structure

> ③ Immune cells like mast cells transport prostaglandin to neighboring cells' cytoplasm to trigger inflammation

 ⑷ **Example 3.** [Estrogen Receptor](https://jb243.github.io/pages/553#:~:text=%E2%91%B9-,%EC%97%90%EC%8A%A4%ED%8A%B8%EB%A1%9C%EA%B2%90,-\(estrogen\)%20%3A)(ER, estrogen receptor)

> ① [Lipophilic Hormone](https://jb243.github.io/pages/89#:~:text=%E2%91%A1-,%EC%A7%80%EC%9A%A9%EC%84%B1%20%ED%98%B8%EB%A5%B4%EB%AA%AC,-%E2%97%8B%20%EA%B2%BD%EB%A1%9C%20%3A%20%ED%98%88%EC%9E%A5)

>> ○ Pathway: Binds to plasma transport proteins, moves to tissues → Intracellular receptor → Gene expression

>> ○ Synthesized and secreted as needed

>> ○ Steroid hormones, thyroid hormone, nitric oxide (NO), adrenal cortex hormones

> ② Genetic Pathway: Estrogen binds to ERα or ERβ, acts on target DNA's ERE or AP-1 for transcriptional activity

> ③ Non-genetic Pathway: Estrogen + ERα/ERβ or Estrogen + GPR30 activate signaling pathways involving MAPK, cAMP

 ⑸ **Example 4.** [Granzyme](https://jb243.github.io/pages/86#:~:text=%E2%97%8B%205%2D2.-,%EA%B7%B8%EB%A0%8C%EC%9E%90%EC%9E%84,-\(granzyme\))

> ① A type of proteolytic enzyme, enters infected cells through endocytosis

> ② Induces apoptosis in target cells, cleaving nuclei and cytoplasm

 ⑹ **Example 5.** cGAS-STING pathway

> ① 1<sup>st</sup>. Binding of dsDNA (double-strand DNA) and cGAS (cyclic GMP-AMP synthase) enzyme

> ② 2<sup>nd</sup>. dsDNA-cGAS complex binds to cGMP

>> ○ Inhibited by ENPP1 binding

> ③ 3<sup>rd</sup>. dsDNA-cGAS-cGMP complex activates STING (stimulator of interferon gene)

>> ○ STING: Also known as TMEM173, MPYS/MITA/ERIS. Encoded by the STING1 gene

> ④ 4<sup>th</sup>. Activated STING moves to the Golgi apparatus

> ⑤ 5<sup>th</sup>. TBK1/IRF3, IKK-IκB signaling pathways activate

> ⑥ 6<sup>th</sup>. Ultimately releases IFN-β and IL-6 cytokines

> ⑦ Function

>> ○ Innate immune response: Generates type I interferon when cells are infected by pathogens through this pathway

>> ○ Prevents spread of infection from infected cells to neighboring cells

<br>

<br>

## **7. Ion Channels**

 ⑴ Ligand-Gated Ion Channels

> ① Nicotinic Acetylcholine Receptor (nAhR): Also known as ionotropic acetylcholine receptor

>> ○ Overview

>>> ○ Found in autonomic ganglia, neuromuscular junctions, central nervous system, etc.

>>> ○ Not present in sinoatrial node, cardiac muscle fibers

>>> ○ Enables rapid neural transmission as an excitatory receptor

>>> ○ Upon acetylcholine binding, both Na+ and K+ can pass through, with Na+ permeability being greater, causing depolarization

>>> ○ Named "nicotinic" due to its response to nicotine

>> ○ Structure: Pentamer

>>> ○ Muscle-type: (α1)2β1δε or (α1)2β1δγ

>>> ○ Ganglion-type: (α3)2(β4)3

>>> ○ Heteromeric CNS-type: (α4)2(β2)3

>>> ○ Further CNS-type: (α3)2(β4)3

>>> ○ Homomeric CNS-type: (α7)5

>> ○ Types

>>> ○ N1 Receptor: Located in neuromuscular junctions

>>> ○ N2 Receptor: Found in brain, dendrites, sympathetic nerves

>> ○ Examples

>>> ○ Sodium channels involved in generating action potentials

>>> ○ Acetylcholine receptors in skeletal muscles

>> ○ Inhibitors

>>> ○ Sarin, DIFP, tubocurarine: Irreversible inhibitors of acetylcholinesterase

>>> ○ Curare: Closes nicotinic receptors, muscle relaxant

> ② Na+ Channel

>> ○ Plant tube-closing response to Cr-La: Inhibitor of sodium channels, acts as a substrate-dependent sodium channel blocker

 ⑵ Voltage-Gated Ion Channels (e.g., Axons)

> ① Tetrodotoxin: Irreversible inhibitor of voltage-gated Na+ channels

> ② Tetraethylammonium: Blocks voltage-gated K+ channels

> ③ [Botulinum toxin](https://jb243.github.io/pages/1122#:~:text=%E2%91%B7-,%EB%B3%B4%ED%86%A1%EC%8A%A4,-%E2%91%A0%20%EA%B0%9C%EC%9A%94%C2%A0): Blocks voltage-gated Ca2+ channels at neuromuscular junctions → Inhibits acetylcholine release → Causes muscle paralysis

 ⑶ Mechanosensitive Ion Channels

> ① [Auditory Receptor](https://jb243.github.io/pages/1290)

> ② [Vestibular Receptor](https://jb243.github.io/pages/1291)

> ③ [Cutaneous Receptor](https://jb243.github.io/pages/1294)

<br>

<br>

## **8. Adhesion Receptors**

 ⑴ **Type 1.** [Integrin](https://jb243.github.io/pages/1409#:~:text=%E2%91%A3-,%EC%9D%B8%ED%85%8C%EA%B7%B8%EB%A6%B0,-\(integrin\)%20%3A%20%EB%A7%89%EA%B4%80%ED%86%B5%20%EB%8B%A8%EB%B0%B1%EC%A7%88)(integrin)

> ① 1<sup>st</sup>. Src, PYK2, FAK, SOS, GRB2, RACK1

> ② 2<sup>nd</sup>. Rac + GTP

> ③ 3<sup>rd</sup>. PAK

> ④ 4<sup>th</sup>. Raf1, MEK1

> ⑤ 5<sup>th</sup>. Erk1/2, MSK1/2

> ⑥ 6<sup>th</sup>. Fos, Ets, Elk, HIF1, STAT3, CREB, c-Jun

<br>

<br>

## **9. Other Receptors**

 ⑴ TNF Receptors

> ① TNFR

>> ○ TNFR1: Associated with inflammation, apoptosis, 55 kDa

>> ○ TNFR2: Associated with anti-inflammatory response, 75 kDa

>> ○ Additionally, receptors with similar structures that perform inflammatory responses constitute the TNFR superfamily (e.g. Fas receptor)

> ② TNF (tumor necrosis factor)

>> ○ TNF-α: Exists in membrane-bound form (mTNF-α) and soluble form (sTNF-α) that dissolves in water

>> ○ TNF-β

> ③ Cell death signaling pathway

>> ○ TNFR → TRADD → FADD → Caspase 8 → Caspase 3 → apoptosis

>> ○ TNFR → TRADD → TRAF2 → clAPS → apoptosis

>> ○ TNFR → TRADD → TRAF2 → MEKK1/4 → MEKK4/7 → JNK → apoptosis

>> ○ 1st. Fas or TNF binds to receptors

>> ○ 2nd. CASP8 (caspase 8) binds with an adaptor to form DISC

>> ○ 3rd. DISC activates caspase 3

>> ○ 4th. CASP3 (caspase 3) initiates cell death

> ④ Cell survival and inflammatory response signaling pathway

>> ○ TNFR → TRAF2 → MEKK1/4 → MEKK4/7 → JNK → AP-1 → inflammation & survival

>> ○ TNFR → TRAF2 → ASK1 → MEKK4/7 → JNK → AP-1 → inflammation & survival

>> ○ TNFR → TRAF2 → RIP → MEKK3/6 → MAPK → inflammation & survival

>> ○ TNFR → TRAF2 → NIK → IKK → NF-κB → inflammation & survival

>> ○ TNFR → TRAF2 → RIP → IKK → NF-κB → inflammation & survival

 ⑵ [Toll-like Receptor](https://jb243.github.io/pages/86#:~:text=%E2%97%8B-,TLR,-%EC%9D%98%20%EC%A2%85%EB%A5%98)(TLR)

> ① Types of TLRs

>> ○ [TLR-1](https://en.wikipedia.org/wiki/TLR_1): multiple triacyl lipopeptide

>> ○ [TLR-2](https://en.wikipedia.org/wiki/TLR2): lipoteichoic acid. Activates innate immunity

>> ○ [TLR-3](https://en.wikipedia.org/wiki/TLR3): Recognizes dsRNA present in viruses

>> ○ [TLR-4](https://en.wikipedia.org/wiki/TLR4): Recognizes LPS (lipopolysaccharide) from gram-negative bacteria

>> ○ [TLR-5](https://en.wikipedia.org/wiki/TLR5): Recognizes flagellin, a component of bacterial flagella

>> ○ [TLR-6](https://en.wikipedia.org/wiki/TLR6): multiple diacyl lipopeptide

>> ○ [TLR-7](https://en.wikipedia.org/wiki/TLR7): Recognizes single-stranded RNA

>> ○ [TLR-8](https://en.wikipedia.org/wiki/TLR8): Recognizes small synthetic compounds and single-stranded RNA

>> ○ [TLR-9](https://en.wikipedia.org/wiki/TLR9): Recognizes unmethylated CpG DNA sequences and oligodeoxynucleotide DNA

> ② **Pathway 1.** MyD88-dependent pathway

>> ○ Overview: Mechanism pathway via **signal transduction**. Activates NF-κB. Increases TNF-α and IL-1β

>> ○ TLR → MyD88 → TRAF6 → NF-κB → NF-κB translocates to the nucleus

>> ○ TLR → MyD88 → TRAF6 → MAPK → AP-1

> ③ **Pathway 2.** TRIF-dependent pathway

>> ○ Overview: Mechanism pathway via **endosome**

>> ○ TLR → TAM, TRIF → IRF3 → IRF3 translocates to the nucleus → type I IFN

>> ○ TLR → TAM, TRIF → TRAF6 → NF-κB → NF-κB translocates to the nucleus

>> ○ TLR → TAM, TRIF → TRAF6 → MAPK → AP-1

 ⑶ Notch signaling

> ① Function: Determines **cell fate**, cell division, cell differentiation, cell death, etc.

> ② Mammals have four types of Notch receptors: NOTCH1, NOTCH2, NOTCH3, NOTCH4

 ⑷ Wnt signaling: Associated with Frizzled receptor

 ⑸ Hedgehog signaling

 ⑹ Enzyme-coupled receptor

> ① **Case 1:** Receptor itself has catalytic domain

> ② **Case 2:** Enzyme assists

> ③ Both cases lead to ECR dimerization for signal transduction

 ⑺ AGE-RAGE

 ⑻ Rap1

 ⑼ NOD-like receptor

 ⑽ YAP/TAZ signaling

 ⑾ Hippo signaling

 ⑿ FGFR pathway

 ⒀ E-cadherin-integrin pathway

<br>

<br>

## **10. Signal Transduction Enhancers**

 ⑴ AMPK: A769662

<br>

<br>

## **11. Signal Transduction Inhibitors**

 ⑴ mTORC1 inhibitor: rapamycin (sirolimus)

 ⑵ MEK1/2 inhibitor: trametinib (Mekinist), cobimetinib, refametinib

 ⑶ ERK1/2 inhibitor: MK-8353, SCH772984

 ⑷ AKT1/2 inhibitor: MK-2206

 ⑸ MAPK9 inhibitor: AS602801

 ⑹ PI3K inhibitor: LY294002, taselisib, alpelisib, MK-2206, idelalisib (CAL-101), dactolisib (BEZ-235), everolimus, pictilisib (GDC-0941), apitolisib (GDC-0980)

 ⑺ IκB inhibitor: Bortezomib

 ⑻ sPLA2-IIa inhibitor: cFLSYR, c(2NapA)LS(2NapA)R

 ⑼ AMPK inhibitor: dorsomorphin

 ⑽ Phosphorylation signal inhibitors: lapatinib

 ⑾ PARP1/2 inhibitor: olaparib

 ⑿ PLK4 inhibitor: CFI400945

 ⒀ p38 inhibitor: VX-745

 ⒁ CHEK1/2 inhibitor: AZD-7762

> ① CHEK1-selective inhibitor: SAR-020106, rabusertib

> ② CHEK2-selective inhibitor: CCT-241533

 ⒂ BRAF inhibitor: dabrafenib, vemurafenib (Zelboraf), PLX4720

 ⒃ JNK inhibitor: JNK-IN-8

 ⒄ WEE1, PLK1 inhibitor: MK-1775

 ⒅ BCL2, BCL-XL, BCL-W inhibitor: navitoclax

 ⒆ TGF-βR inhibitor: RepSox

 ⒇ Tyrosine phosphorylase inhibitors: imatinib (Glivec), dasatinib (Sprycel), sunitinib (Sutent), nilotinib (Tasigna), sorafenib (Nexavr), temsirolimus (Torisel)

<br>

---

_Input: 2021.01.24 23:48_

_Modified: 2022.06.13 14:05_
